LL
Eli Lilly
LLY · NYSE
$1,148.74 -0.94% (-$10.86)
1M -3.16%
Market Cap $1.09T
P/E Ratio 40.88x
Div. Yield 0.56%
ROE 92.58%
Bulios Fair Price
$759.93
33.8% downside
Current Price
$1,149
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LLY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
11 /100
Expensive P/E 40.88x
PEG 0.56x
EV/EBITDA 32.32x
Growth
100 /100
Growing EPS growth 51.73%
Book val. growth 35.57%
Rev. growth 31.69%
Profitability
100 /100
Strong Gross margin 84.01%
FCF margin 25.17%
Net margin 33.53%
Quality
92 /100
Excellent ROIC 27.38%
Asset turnover 0.56x
ROE 92.58%
Debt
67 /100
Low Debt/Equity 1.62x
Net debt/EBITDA 1.31x
Current ratio 1.35x
Stability
64 /100
Moderate Beta 0.50x
Profitable years 6
Rev. volatility 12.57%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LLY
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
David A. Ricks
Employees
50,000
Headquarters
Indianapolis
Upcoming events
29 OCT
Earnings
Upcoming earnings report